Loading...
•
Dec 31, 2021
Veracyte Q4 2021 Earnings Report
Veracyte's Q4 2021 financial results were announced, revealing a significant revenue increase and strategic advancements.
Key Takeaways
Veracyte reported a 95% increase in revenue for Q4 2021, reaching $67.3 million. The company's net loss increased by 31% to $10.5 million, and basic and diluted net loss per common share increased by 7% to $0.15. Key business highlights included a 70% increase in test volume and the completion of the Decipher Biosciences and HalioDx acquisitions.
Total revenue increased by 95% to $67.3 million compared to Q4 2020.
Net loss was $10.5 million, a 31% increase from the previous year.
Basic and diluted net loss per common share was $0.15, a 7% increase.
Test volume grew by 70% in Q4 2021.
Revenue by Segment
Forward Guidance
Veracyte is initiating 2022 annual total revenue guidance of $260 million to $275 million, representing year-over-year growth of 18% to 25%, compared to the prior year.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...